MYGN vs. FOLD, CLDX, MNKD, BCRX, NVAX, INVA, OPK, DVAX, ZBIO, and GERN
Should you be buying Myriad Genetics stock or one of its competitors? The main competitors of Myriad Genetics include Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), MannKind (MNKD), BioCryst Pharmaceuticals (BCRX), Novavax (NVAX), Innoviva (INVA), OPKO Health (OPK), Dynavax Technologies (DVAX), Zenas BioPharma (ZBIO), and Geron (GERN). These companies are all part of the "biotechnology" industry.
Myriad Genetics vs. Its Competitors
Myriad Genetics (NASDAQ:MYGN) and Amicus Therapeutics (NASDAQ:FOLD) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.
Myriad Genetics presently has a consensus price target of $12.45, indicating a potential upside of 54.52%. Amicus Therapeutics has a consensus price target of $15.78, indicating a potential upside of 92.41%. Given Amicus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Amicus Therapeutics is more favorable than Myriad Genetics.
Amicus Therapeutics has a net margin of -6.67% compared to Myriad Genetics' net margin of -47.45%. Amicus Therapeutics' return on equity of -5.07% beat Myriad Genetics' return on equity.
In the previous week, Myriad Genetics had 3 more articles in the media than Amicus Therapeutics. MarketBeat recorded 4 mentions for Myriad Genetics and 1 mentions for Amicus Therapeutics. Myriad Genetics' average media sentiment score of 0.65 beat Amicus Therapeutics' score of 0.50 indicating that Myriad Genetics is being referred to more favorably in the media.
Myriad Genetics has a beta of 1.97, indicating that its share price is 97% more volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500.
Amicus Therapeutics has lower revenue, but higher earnings than Myriad Genetics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.
99.0% of Myriad Genetics shares are owned by institutional investors. 2.4% of Myriad Genetics shares are owned by company insiders. Comparatively, 2.2% of Amicus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Amicus Therapeutics beats Myriad Genetics on 9 of the 16 factors compared between the two stocks.
Get Myriad Genetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MYGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Myriad Genetics Competitors List
Related Companies and Tools
This page (NASDAQ:MYGN) was last updated on 10/6/2025 by MarketBeat.com Staff
